Market Overview

UPDATE: Stifel Nicolaus Initiates Boston Scientific Corporation at Buy on Steady Progress

Share:
Related BSX
The Most Popular Stocks This 13F Season
Barclays Says Investors Underestimate St. Jude Medical 's Potential
Medtronic Earnings Face FX Headwinds, But Cardiac Trends Good (Investor's Business Daily)

Stifel Nicolaus initiated coverage on Boston Scientific Corporation (NYSE: BSX) with a Buy rating and a $6.50 price target.

Stifel Nicolaus commented, "We see BSX as poised for more attractive growth, operating and financial performance in the years ahead. Following an extended period of relative underperformance, we think this long-term turnaround story with still-depressed sales growth and profitability could be approaching a return to more sustainable low-single-digit top-line growth in 2014 and beyond, driving a more positive sentiment on the shares."

Boston Scientific CorporationStifel Nicolaus closed at $5.14 on Monday.

Latest Ratings for BSX

DateFirmActionFromTo
Aug 2016CitigroupMaintainsBuy
Jul 2016JP MorganMaintainsOverweight
Jul 2016JefferiesMaintainsHold

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (BSX)

View Comments and Join the Discussion!